Enalapril 10 mg Recall in South Africa: What You Should Know
The South African Health Products Regulatory Authority (SAHPRA) has announced the recall of four specific batches of Enalapril 10 mg Arya, a prescription medicine used in the management of high blood pressure.
SAHPRA announced the recall on 16 August 2026 after what the regulator described as out-of-specification results identified during post-marketing surveillance. The recall applies only to the four identified batches and should not be interpreted as a recall of all enalapril medicines.
For healthcare students and professionals, the notice is also a practical example of how medicine quality, post-market monitoring and batch traceability work in real healthcare settings.
Which batches are affected?
According to SAHPRA, the recall applies to Enalapril 10 mg Arya in 28-tablet packs with the following batch numbers:
- GQQ24053 — expiry August 2026
- GQQ24064 — expiry September 2026
- GQQ24066 — expiry September 2026
- GQQ24067 — expiry September 2026
SAHPRA has classified the action as a Class II Type A recall. The regulator emphasises that the recall concerns only these four batches.
Why were these batches recalled?
SAHPRA states that the recall was initiated because of a quality defect following out-of-specification results observed during post-marketing surveillance.
The public notice does not state that enalapril as a medicine has broadly been found unsafe or ineffective. This is an important distinction: a medicine recall can relate to specific batches or a particular product rather than every medicine containing the same active ingredient.
What does a medicine recall mean?
Medicines continue to be monitored after they have entered the market. Regulators can act when a quality, safety or other regulatory concern is identified, and the response depends on the specific issue and its assessed risk.
Batch numbers help manufacturers, suppliers, pharmacies and regulators trace products through the supply chain. When a problem is limited to particular batches, this traceability allows affected stock to be identified and removed without automatically treating every pack of that medicine as affected.
This is why checking the exact product name, strength and batch number matters when reading a medicine recall notice.
What should patients know?
SAHPRA advises patients currently taking Enalapril 10 mg Arya to check the batch number on their medicine packaging.
Anyone with medicine from one of the affected batches should contact their pharmacist or healthcare professional for advice and, where necessary, an alternative medicine.
SAHPRA specifically advises patients not to stop taking their blood-pressure medicine without first consulting their doctor, pharmacist or other healthcare professional.
What should healthcare professionals and suppliers do?
SAHPRA has asked healthcare professionals, pharmacies, wholesalers and other medicine suppliers to identify stock from the affected batches, stop dispensing or distributing it, quarantine affected stock and return it through the established supply chain.
For healthcare students, this provides a useful real-world example of why medicine safety extends beyond learning indications, mechanisms and dispensing procedures.
What healthcare students can learn from this recall
A medicine moves through a much larger system before and after reaching a patient: manufacturing, quality control, regulatory oversight, procurement, distribution, dispensing and ongoing surveillance all play a role.
The Enalapril 10 mg Arya recall illustrates three particularly useful concepts:
- Post-marketing surveillance: regulatory monitoring continues after a health product reaches the market.
- Batch traceability: individual production batches can be identified when a quality concern arises.
- Clear communication: healthcare professionals need to distinguish a targeted recall from a broader problem with a medicine and direct patients to the appropriate professional guidance.
SAHPRA also encourages healthcare professionals and members of the public to report suspected side effects associated with health products through its established reporting channels. These reports contribute to ongoing monitoring of medicines in South Africa.
The practical takeaway
The current recall concerns four specific batches of Enalapril 10 mg Arya. Patients using this product should check their batch number and follow SAHPRA’s official guidance if their medicine is affected.
For healthcare students and professionals, the recall is a useful reminder that medicine safety does not end when a prescription is written or a product is dispensed. Quality monitoring, traceability and accurate communication remain important throughout a medicine’s lifecycle.
For the latest recall status and regulatory guidance, readers should refer directly to the official SAHPRA recall notice.
Medical & Editorial Disclaimer
This article is provided by MyMedGear for general educational and informational purposes only. It does not provide medical, pharmaceutical, diagnostic or treatment advice. Recall information is based on publicly available information issued by SAHPRA and may change after publication. Readers should verify current information with SAHPRA and consult an appropriately qualified healthcare professional or pharmacist regarding individual medicines or treatment decisions. MyMedGear is not the manufacturer of Enalapril 10 mg Arya and is not affiliated with the manufacturer or distributor of the recalled product.
Last reviewed: 31 August 2026